Compare iShares MSCI China ETF (MCHI) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI China ETF vs Twist Bioscience Corp — how do they compare? iShares MSCI China ETF trades at $54.41, while Twist Bioscience Corp trades at $88.43 (market cap $5.45B). The key difference: Twist Bioscience Corp is trading nearer its 52-week high, iShares MSCI China ETF nearer its low. Which is the better fit depends on your goals.
| MCHI | TWST | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $66.99 | $102.88 |
52-Week Low | $50.48 | $24.16 |
Market Cap | — | $5.45B |
Enterprise Value | — | $5.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MCHI trades at $54.08, up 2.13% today, but technical indicators signal a bearish trend with moving averages showing sell pressure. The stock lacks key valuation metrics like P/E and P/S, and recent news highlights China's economic stimulus focus and AI sector growth, which could impact this China-focused ETF. Dividend activity is scheduled for mid-2026.
The outlook is cautious due to bearish technicals and macroeconomic risks from U.S.-China tensions, though AI-driven exports offer growth potential. Investors face value trap risks amid mixed analyst sentiment, requiring close monitoring of China's policy developments and corporate earnings for directional cues.
Twist Bioscience (TWST) trades at $87.41, down 6.86% today, with a bullish technical outlook despite recent earnings misses. The company shows strong revenue growth from $204M in 2022 to $377M in 2025, though it remains unprofitable with a -19.85% net margin. Analyst consensus is strongly bullish with 11 buy ratings and a $91.63 price target, while recent news highlights AI-driven drug discovery collaborations and upcoming Q3 earnings.
The stock presents growth potential through expanding synthetic biology applications and AI partnerships, but carries significant risk from persistent losses, negative cash flow, and high valuation multiples (P/S 13.94). Investors should weigh the company's innovation trajectory against its path to profitability amid competitive biotech pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI China ETF
MCHI is an ETF that seeks to track the investment results of the MSCI China Index. It provides broad exposure to the Chinese equity market, primarily focusing on large and mid-cap companies listed in Hong Kong and Shanghai. MCHI serves as a core holding for investors looking to gain diversified exposure to the performance and growth potential of the companies within the People's Republic of China.
Read more on MCHI →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
